Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). [Read more…] about The new frontier in neurocognitive monitoring and dementia screening: the Apple Watch
Alzheimer’s cure behind the boom in brain science (Financial Review):
“Biogen is one of many members of big pharma seeking the blockbuster drug which will inevitably be worth multiple billions of dollars. Big pharma in the US spends about $US5 billion a year on Alzheimer’s research and development.
Exponential growth in the disease over the past decade has not been accompanied by the development of approved drugs. In fact, [Read more…] about Can better cognitive testing platforms accelerate pharma’s Alzheimer’s research and development efforts?